Spots Global Cancer Trial Database for Screening to Improve Survival in AL Amyloidosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Screening to Improve Survival in AL Amyloidosis
Official Title: Screening to Improve Survival in AL Amyloidosis
Study ID: NCT04615572
Interventions
Study Description
Brief Summary: The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, United States
University of California, San Francisco, San Francisco, California, United States
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Tufts Medical Center, Boston, Massachusetts, United States
Columbia University Irving Medical Center, New York, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
